Pancreatic Cancer Research

ResearcherOsaka International Cancer InstituteActive in the last 2 years

Kenji Ikezawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7517-8960; OpenAlex author ID A5054555444. Sources: OpenAlex.

Their work

Papers
37 (first author 18, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
71
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 4 papers · 2021: 3 papers · 2022: 6 papers · 2023: 4 papers · 2024: 5 papers · 2025: 5 papers · 2026: 7 papers

Papers 37

  1. Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden-High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment. First author DOI 10.1002/cnr2.70492↗
  2. Prospective Phase II Trial of Biweekly Gemcitabine Plus Nab-Paclitaxel as First-Line Therapy in Patients Aged 75 Years and Older With Unresectable Pancreatic C… Co-author DOI 10.1002/cnr2.70691↗
  3. Effects of Pancreatic Duct Stenting on Nutrition and Pancreatic Function in Unresectable Pancreatic Cancer: A Pilot Study. First author DOI 10.1002/jgh3.70358↗
  4. Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarc… First author DOI 10.1007/s10147-026-03071-6↗
  5. Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived from saline flushes collected during routin… First author DOI 10.1007/s12094-025-04111-9↗
  6. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study. First author DOI 10.1016/j.esmogo.2026.100365↗
  7. KRAS Mutations in Duodenal Lavage Fluid After Secretin Stimulation for Detection of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006645↗
  8. Electronic Patient-Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second-Line Chemotherapy: A Multicenter Observational … Co-author DOI 10.1002/cam4.71161↗
  9. Clinical Outcome and Safety of Triweekly Modified FOLFIRINOX Therapy in Patients with Advanced Pancreatic Cancer. First author DOI 10.1007/s12029-025-01309-6↗
  10. Impact of zinc deficiency on the prognosis of unresectable pancreatic cancer. First author DOI 10.1016/j.pan.2025.05.007↗
  11. The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization. Co-author DOI 10.1186/s12876-025-04108-2↗
  12. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  13. Zinc supplementation for dysgeusia in patients with unresectable pancreatic cancer. First author DOI 10.1007/s10147-024-02544-w↗
  14. The relationship between observation interval and prognosis in pancreatic cancer concomitant with intraductal papillary mucinous neoplasia. Co-author DOI 10.1016/j.pan.2023.11.005↗
  15. Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. First author DOI 10.1038/s41598-024-73020-8↗
  16. Gastrointestinal: Enlarged pancreatic tail mass during chemotherapy for pancreatic cancer. First author DOI 10.1111/jgh.16566↗
  17. Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer. Co-author DOI 10.1186/s12885-024-12722-8↗
  18. Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry. First author DOI 10.1007/s00432-023-04966-x↗
  19. Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer. First author DOI 10.1186/s12885-023-11205-6↗
  20. Main pancreatic duct dilatation and pancreatic cysts in relatives and spouses of patients with pancreatic cancer. Co-author DOI 10.1371/journal.pone.0280403↗
  21. Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. First author DOI 10.3390/cancers15030970↗
  22. Chemotherapy effectiveness and age-group analysis of older adult patients with metastatic pancreatic cancer: A Japanese cancer registry cohort study. First author DOI 10.1016/j.jgo.2022.07.010↗
  23. Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic ca… Co-author DOI 10.1055/a-1713-3404↗
  24. Refractory Lower Limb Edema Resolved by Endovascular Stent Placement for Inferior Vena Cava Stenosis in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002152↗
  25. Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic ca… First author DOI 10.1371/journal.pone.0264653↗
  26. New Screening System Using Forward-Viewing Radial Endoscopic Ultrasound and Magnetic Resonance Imaging for High-Risk Individuals With Familial History of Pancr… Co-author DOI 10.3389/fmed.2022.928182↗
  27. 5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine an… First author DOI 10.3390/curroncol29040216↗
  28. Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastat… Co-author DOI 10.1002/jgh3.12555↗
  29. Predictive Factors for Pancreatic Cancer and Its Early Detection Using Special Pancreatic Ultrasonography in High-Risk Individuals. First author DOI 10.3390/cancers13030502↗
  30. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Ca… First author DOI 10.3390/cancers13184733↗
  31. Effectiveness of Contrast-Enhanced Ultrasonography for the Characterization of Small and Early Stage Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.ultrasmedbio.2020.04.016↗
  32. Efficacy of Larger-Diameter Plastic Stent Placement for Preoperative Biliary Drainage in Patients Receiving Neoadjuvant Chemoradiation for Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001509↗
  33. Risk Factors for Pancreatic Cancer and the Necessity of Long-Term Surveillance in Patients With Pancreatic Cystic Lesions. Co-author DOI 10.1097/mpa.0000000000001521↗
  34. Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response to Chemotherapy. Co-author DOI 10.1097/mpa.0000000000001652↗
  35. Soluble UL16-binding protein 2 is associated with a poor prognosis in pancreatic cancer patients. Co-author DOI 10.1016/j.bbrc.2019.07.020↗
  36. A case of stage IA pancreatic ductal adenocarcinoma accompanied with focal pancreatitis demonstrated by contrast-enhanced ultrasonography. Co-author DOI 10.1007/s10396-018-0870-5↗
  37. Risk of peritoneal carcinomatosis by endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer. Co-author DOI 10.1007/s00535-012-0693-x↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kazuyoshi Ohkawa · 31 shared papers, 2013–2026 · strength 5.29
  2. Ryoji Takada · 25 shared papers, 2020–2026 · strength 4.36
  3. Yugo Kai · 20 shared papers, 2021–2026 · strength 3.65
  4. Makiko Urabe · 19 shared papers, 2020–2026 · strength 3.55
  5. Takuo Yamai · 17 shared papers, 2020–2026 · strength 2.51
  6. Yusuke Seiki · 8 shared papers, 2023–2026 · strength 1.65
  7. Hidenori Takahashi · 8 shared papers, 2020–2026 · strength 1.34
  8. Ko Watsuji · 7 shared papers, 2023–2026 · strength 1.34
  9. Nobuyasu Fukutake · 10 shared papers, 2013–2026 · strength 1.27
  10. Shigenori Nagata · 8 shared papers, 2018–2026 · strength 1.26
  11. Reiko Ashida · 9 shared papers, 2020–2026 · strength 1.24
  12. Kana Hosokawa · 4 shared papers, 2025–2026 · strength 0.96
  13. Yasuharu Kawamoto · 6 shared papers, 2022–2024 · strength 0.92
  14. Kazuma Daiku · 6 shared papers, 2021–2022 · strength 0.79
  15. Takumi Kinomoto · 3 shared papers, 2025–2026 · strength 0.71
  16. Chigusa Morizane · 3 shared papers, 2025–2026 · strength 0.65
  17. Kazuhiro Katayama · 6 shared papers, 2018–2021 · strength 0.61
  18. Hirofumi Akita · 3 shared papers, 2021–2026 · strength 0.59
  19. Sachiko Tanaka · 5 shared papers, 2013–2023 · strength 0.52
  20. Tatsuya Ioka · 5 shared papers, 2013–2022 · strength 0.49
  21. Yoji Kukita · 3 shared papers, 2020–2026 · strength 0.49
  22. Junko Fukuda · 4 shared papers, 2018–2023 · strength 0.49
  23. Takeshi Terashima · 2 shared papers, 2025–2026 · strength 0.45
  24. Masato Ozaka · 2 shared papers, 2025–2026 · strength 0.45
  25. Shinichiro Hasegawa · 2 shared papers, 2022–2026 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.